Platelets and Clotting Factors

Thrombocytes (Platelets)

Thrombocytes, commonly known as platelets, are small, anucleate cell fragments essential for blood clotting and vascular repair. They originate from large bone marrow cells called megakaryocytes and play a central role in hemostasis.

• Development and Structure: Platelets are cytoplasmic fragments of megakaryocytes. Their outer region stains blue/purple, and they contain purple granules (large vesicles) filled with signaling molecules.

• Key Signaling Molecules:

  • Activate other platelets

  • Increase vascular spasm

  • Promote formation of the platelet plug

  • Promote regrowth of blood vessels

  • Attract immune cells to the site of injury

• Thrombopoietin: A hormone produced by the liver and kidneys that stimulates the production and maturation of megakaryocytes, leading to platelet formation.

• Platelet Lifespan: Platelets take about a week to be produced and another week to be removed from circulation.

• Normal Platelet Count: 150–400 billion platelets per liter of blood (about 1/10 the number of red blood cells).

Developmental Pathway: Hematopoietic stem cell → Megakaryoblast → Megakaryocyte (stages I-IV) → Platelets

Example: A decrease in thrombopoietin production can lead to thrombocytopenia, a condition characterized by low platelet counts and increased bleeding risk.

Thrombocyte Function

Platelets are crucial for maintaining vascular integrity and preventing blood loss after injury. They form a temporary plug at sites of vessel damage and initiate the clotting cascade.

• Temporary Plug Formation: Platelets aggregate at the site of vessel injury to form a plug that seals small breaks.

• Prevention of Unwanted Clotting: Platelets are kept inactive and mobile by nitric oxide (NO) and prostacyclin, both released by endothelial cells lining blood vessels.

• Key Terms:

  • Nitric oxide (NO): A gaseous signaling molecule that inhibits platelet activation.

  • Prostacyclin: A lipid that prevents platelet aggregation.

Example: Damage to the endothelium reduces NO and prostacyclin release, allowing platelets to activate and aggregate.

Hemostasis

Overview of Hemostasis

Hemostasis is the physiological process that stops bleeding at sites of vascular injury. It involves a series of tightly regulated reactions that utilize mechanical and chemical substances released by platelets and injured tissues.

• Main Steps of Hemostasis:

  1. Vascular Spasm (Vasoconstriction): Immediate constriction of damaged blood vessels to reduce blood flow.

  2. Platelet Plug Formation: Platelets adhere to exposed collagen fibers and aggregate to form a temporary plug.

  3. Coagulation: Plasma clotting factors are activated, leading to the formation of a stable fibrin clot.

Vascular Spasm

Vascular spasm is the first response to vessel injury, involving the constriction of blood vessels to minimize blood loss.

• Mechanisms:

  • Mechanical injury to smooth muscle

  • Chemicals released by endothelial cells and platelets

• Effectiveness: Most effective in small blood vessels; not effective in capillaries due to their lack of smooth muscle.

Example: Applying pressure to a wound enhances vascular spasm and helps control bleeding.

Platelet Plug Formation

Platelet plug formation is a rapid process where platelets adhere to exposed collagen fibers at the injury site, aggregate, and release chemical messengers to recruit more platelets.

• von Willebrand Factor: A plasma protein that acts as a glue, facilitating platelet adhesion to collagen. Deficiency leads to von Willebrand disease, the most common inherited clotting disorder.

• Platelet Activation: Platelets become spiked and sticky, releasing messengers such as Platelet Activating Factor (PAF), ADP, serotonin, and thromboxane A2.

• Positive Feedback Loop: Released chemicals recruit additional platelets and enhance vascular spasm.

• Aspirin: Inhibits thromboxane A2, reducing platelet aggregation and clot formation.

Example: Individuals with von Willebrand disease experience frequent nosebleeds and easy bruising due to impaired platelet plug formation.

Coagulation (Blood Clotting)

Coagulation is the process by which plasma clotting factors are activated in a cascade, resulting in the formation of a stable fibrin clot.

• Pathways: Coagulation can be initiated by intrinsic or extrinsic pathways, both converging on the activation of factor X (prothrombin activator).

• Key Steps:

  1. Prothrombin (factor II) is converted to thrombin (an enzyme).

  2. Thrombin catalyzes the conversion of fibrinogen (factor I) to fibrin.

  3. Fibrin, with the help of Ca2+ and factor XIII, forms crosslinked strands that stabilize the clot.

Key Equations:

Example: Deficiency in factor VIII leads to hemophilia A, a disorder characterized by impaired coagulation.

Clot Retraction and Vessel Repair

After a clot forms, platelets contract using cytoskeletal proteins (actin and myosin), shrinking the clot and pulling the edges of the ruptured vessel together.

• Clot Retraction: Occurs within 30–60 minutes, squeezing serum (plasma without clotting factors) from the clot.

• Platelet-Derived Growth Factor (PDGF): Stimulates cell division of smooth muscle cells and fibroblasts to rebuild the vessel wall.

• Vascular Endothelial Growth Factor (VEGF): Promotes endothelial cell proliferation and restoration of the vessel lining.

Example: PDGF and VEGF are critical for wound healing and tissue regeneration after vascular injury.

Fibrinolysis

Fibrinolysis is the process of breaking down and removing clots after vessel repair is complete.

• Plasminogen: Incorporated into the clot and converted to plasmin by tissue plasminogen activator (tPA).

• Plasmin: A fibrin-digesting enzyme that dissolves the clot.

Key Equation:

Example: tPA is used clinically as a "clot buster" in treating strokes and heart attacks.

Factors Limiting Clot Growth or Formation

Several mechanisms prevent excessive clotting and ensure that clots form only at sites of injury.

• Swift Removal and Dilution: Clotting factors are quickly removed and diluted by blood flow.

• Inhibition of Thrombin:

  • Antithrombin III: Inactivates unbound thrombin.

  • Heparin: Released by basophils and mast cells, enhances antithrombin III activity.

  • Dabigatran: A drug that directly inhibits thrombin.

Example: Heparin is commonly used as an anticoagulant in medical settings to prevent unwanted clot formation.

Clotting Factors and Vitamin K

Clotting factors are proteins essential for the coagulation cascade. Vitamin K is required for the synthesis of several key clotting factors.

• Hemophilia A, B, C: Genetic disorders resulting from deficiencies in factors VIII, IX, and XI, respectively (intrinsic pathway).

• Vitamin K: Needed for synthesis of factors II, VII, IX, and X. Found in green vegetables such as kale, spinach, collard greens, broccoli, and Brussels sprouts.

• Warfarin: A drug that blocks the formation of vitamin K-dependent clotting factors, used as an anticoagulant.

Example: Patients on warfarin must monitor their vitamin K intake to avoid excessive bleeding or clotting.

Hemostasis Disorders

Embolic Disorders

Embolic disorders involve undesirable clot formation within blood vessels, which can obstruct blood flow and cause serious complications.

• Thrombus: A clot that develops and persists in an unbroken blood vessel (e.g., deep vein thrombosis).

• Embolus: A thrombus that breaks free and floats in the bloodstream.

• Embolism: An embolus that obstructs a vessel, potentially causing cardiac, pulmonary, or cerebral complications.

Example: Pulmonary embolism occurs when a blood clot blocks an artery in the lungs, leading to respiratory distress.

Bleeding Disorders

Bleeding disorders are conditions that prevent normal clot formation, leading to excessive bleeding and bruising.

• Thrombocytopenia: Deficient number of circulating platelets, often due to suppression or destruction of red bone marrow (e.g., malignancy, radiation, drugs). Symptoms include petechiae (small, spontaneous hemorrhages).

• Petechiae: Small, red or purple spots caused by capillary breakage and bleeding under the skin.

• Hemophilia: A group of hereditary disorders characterized by missing clotting factors (A: VIII, B: IX, C: XI), leading to prolonged bleeding. Treated with plasma transfusions and factor injections.

• Liver Dysfunction: The liver synthesizes most pro-coagulants. Conditions such as vitamin K deficiency, hepatitis, and cirrhosis impair clotting factor production.

• Impaired Fat Absorption: Prevents the liver from producing bile, which is necessary for fat and vitamin K absorption.

Example: Patients with cirrhosis may develop bleeding tendencies due to reduced synthesis of clotting factors.

Table: Comparison of Hemostasis Disorders

Additional info: The table above summarizes the main hemostasis disorders, their causes, symptoms, and treatments for quick reference.